Actelion’s clinical development activities include the characterization of macitentan in specific PAH patient populations as well as expanding its use beyond PAH. The pipeline also includes novel product candidates; a novel antibiotic, cadazolid, under investigation for Clostridium difficile-associated diarrhea (CDAD) and a S1P1 receptor modulator, ponesimod, investigated in multiple sclerosis.

Phase Compound Indication Study Status
Phase III Cadazolid Clostridium difficile-associated diarrhea IMPACT Complete
Macitentan Pediatric PAH TOMORROW Initiating
Macitentan Portopulmonary hypertension (PoPH) PORTICO Ongoing
Macitentan Fontan-palliated RUBATO Initiating
Ponesimod Multiple sclerosis OPTIMUM Ongoing
Ponesimod Multiple sclerosis POINT Ongoing
Selexipag  Short-term replacement of IV selexipag IV selexipag Ongoing
Phase II Macitentan Chronic thromboembolic pulmonary hypertension MERIT Ongoing


"I find my work inspirational because I know the company I work for is striving to help people."

Supervisor, Corporate IT